<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Pasithea Therapeutics Corporation (KTTA) 週一表示，已任命 Kartik Krishnan 為首席醫學官，任職時間從 5 月 1 日起生效。</p>
<p>Krishnan 在臨牀開發、藥物警戒、臨牀運營等方面擁有超過 20 年的經驗。</p>
<p>在加入 Pasithea 之前，Krishnan 曾擔任 OncoNano Medicines 的首席執行官，該公司是一家開發抗癌資產的私營公司。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

KTTAW

KTTA

標普全球醫療股指數 ETF - iShares

<p>Pasithea Therapeutics Corporation (KTTA) 已任命 Kartik Krishnan 為首席醫學官，任職時間從 5 月 1 日開始。Krishnan 擁有超過 20 年的臨牀開發及相關領域的經驗，曾擔任 OncoNano Medicines 的首席執行官，該公司專注於抗癌資產</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Pasithea Therapeutics Corporation (KTTA) said on Monday that it has appointed Kartik Krishnan as chief medical officer with effect from May 1.</p>
<div class="lb-trans"><p>Pasithea Therapeutics Corporation (KTTA) 週一表示，已任命 Kartik Krishnan 為首席醫學官，任職時間從 5 月 1 日起生效。</p>
</div><p>Krishnan has over 20 years of experience in clinical development, pharmacovigilance, clinical operations, and others.</p>
<div class="lb-trans"><p>Krishnan 在臨牀開發、藥物警戒、臨牀運營等方面擁有超過 20 年的經驗。</p>
</div><p>Prior to joining Pasithea, Krishnan was chief executive officer at OncoNano Medicines, a privately held company developing anti-cancer assets.</p>
<div class="lb-trans"><p>在加入 Pasithea 之前，Krishnan 曾擔任 OncoNano Medicines 的首席執行官，該公司是一家開發抗癌資產的私營公司。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

Pasithea Therapeutics Appoints Kartik Krishnan As CMO

rttnews

PASITHEA THERAPEUTICS CORP C/WTS 12/08/2026 (TO PUR COM)

Pasithea Therapeutics

基因改革 ETF - ARK

醫療業 ETF - SPDR

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

美國制藥 ETF - iShares

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

動態生物技術與基因組 ETF - Invesco

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - Vanguard

醫藥突破 ETF - ALPS

標普生物技術 3 倍做多 - Direxion

Pasithea Therapeutics 任命 Kartik Krishnan 為首席醫療官（CMO）